Immunome (NASDAQ:IMNM) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Immunome (NASDAQ:IMNM) from a hold rating to a sell rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on IMNM. Leerink Partners set a $40.00 price target on shares of Immunome in a report on Monday, December 15th. Guggenheim lifted their price objective on shares of Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. HC Wainwright assumed coverage on shares of Immunome in a report on Thursday, February 12th. They issued a “buy” rating and a $40.00 target price on the stock. Evercore increased their target price on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.33.

Immunome Stock Performance

IMNM opened at $21.33 on Friday. Immunome has a one year low of $5.15 and a one year high of $27.65. The stock’s fifty day moving average is $22.74 and its 200-day moving average is $17.87. The company has a market capitalization of $2.41 billion, a PE ratio of -8.81 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. On average, equities research analysts forecast that Immunome will post -2.21 EPS for the current fiscal year.

Insider Activity at Immunome

In other Immunome news, Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Clay B. Siegall acquired 46,511 shares of Immunome stock in a transaction on Thursday, December 18th. The shares were purchased at an average cost of $21.50 per share, with a total value of $999,986.50. Following the completion of the purchase, the chief executive officer directly owned 853,247 shares of the company’s stock, valued at approximately $18,344,810.50. This represents a 5.77% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 68,518 shares of company stock worth $1,453,958 in the last quarter. 7.69% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

Large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. boosted its stake in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. Invesco Ltd. raised its stake in Immunome by 382.1% during the 4th quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock valued at $5,801,000 after purchasing an additional 214,049 shares during the period. Virtus Investment Advisers LLC raised its stake in Immunome by 16.9% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after purchasing an additional 1,970 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Immunome by 267.8% in the fourth quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock valued at $20,072,000 after purchasing an additional 680,395 shares in the last quarter. Finally, SummitTX Capital L.P. purchased a new stake in shares of Immunome in the fourth quarter valued at $2,741,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.